KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Inventory: 2011-2025

Historic Change in Inventory for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Sep 2025 value amounting to $131.1 million.

  • Vertex Pharmaceuticals' Change in Inventory fell 28.16% to $131.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $594.3 million, marking a year-over-year increase of 35.13%. This contributed to the annual value of $517.3 million for FY2024, which is 60.20% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Change in Inventory stood at $131.1 million, which was down 11.78% from $148.6 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Change in Inventory high stood at $182.5 million for Q3 2024, and its period low was -$2.0 million during Q1 2022.
  • Moreover, its 3-year median value for Change in Inventory was $107.2 million (2024), whereas its average is $117.0 million.
  • In the last 5 years, Vertex Pharmaceuticals' Change in Inventory crashed by 108.77% in 2022 and then skyrocketed by 4,230.00% in 2023.
  • Vertex Pharmaceuticals' Change in Inventory (Quarterly) stood at $27.0 million in 2021, then soared by 190.00% to $78.3 million in 2022, then fell by 10.60% to $70.0 million in 2023, then soared by 110.71% to $147.5 million in 2024, then declined by 28.16% to $131.1 million in 2025.
  • Its Change in Inventory was $131.1 million in Q3 2025, compared to $148.6 million in Q2 2025 and $167.1 million in Q1 2025.